Table 1.
Characteristics of the eligible RCTs.
| Study (year) | Study type | Histology | Endpoint | Treatment arm | Patient (no.) | Pancreatitis | AMY | Lipase | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (G1–5) | (G3–5) | (1–5) | (3–5) | (1–5) | (3–5) | ||||||
| Ribas et al., 2013 [6] | RCT III | MM | OS | Tremelimumab at 15 mg/kg 90 ds | 325 | 3 | 3 | NA | NA | NA | NA |
| Chemotherapy control | 319 | 0 | 0 | NA | NA | NA | NA | ||||
|
| |||||||||||
| Know, 2014 | RCT III | prostate Ca | OS | Ipilimumab 10 mg/kg q3w | 393 | NA | NA | 2 | 2 | 3 | 1 |
| Placebo | 396 | NA | NA | 1 | 0 | 3 | 2 | ||||
|
| |||||||||||
| Eggermont et al., 2015 [7] | RCT III | MM | PFS | Ipilimumab 10 mg/kg q3w | 471 | NA | 1 | NA | NA | 43 | 1 |
| Placebo | 474 | NA | 0 | NA | NA | 30 | 0 | ||||
|
| |||||||||||
| Maio et al., 2017 [8] | RCT IIb | Mesothelioma | OS | Tremelimumab 10 mg/kg q4w | 380 | 2 | 1 | NA | 0 | 18 | 11 |
| Placebo | 189 | 0 | 0 | NA | 1 | 4 | 3 | ||||
|
| |||||||||||
| Brahmer et al., 2015 [24] | RCT III | NSCLC | OS | Nivolumab 3 mg/kg q2w | 131 | NA | NA | NA | NA | 1 | 1 |
| Chemotherapy control | 129 | NA | NA | NA | NA | 0 | 0 | ||||
|
| |||||||||||
| Robert et al., 2011 [4] | RCT III | MM | OS | Nivolumab 3 mg/kg q2w | 206 | NA | NA | NA | 1 | NA | NA |
| Chemotherapy control | 205 | NA | NA | NA | 0 | NA | NA | ||||
|
| |||||||||||
| Weber et al., 2015 [9] | RCT III | MM | ORR | Nivolumab 3 mg/kg q2w | 268 | NA | 2 | NA | NA | NA | 3 |
| Chemotherapy control | 102 | NA | 0 | NA | NA | NA | 1 | ||||
|
| |||||||||||
| Herbst et al., 2016 [10] | RCT III | NSCLC | OS | Pembrolizumab 2 mg/kg q2w | 339 | 3 | 2 | NA | NA | NA | NA |
| Pembrolizumab 10 mg/kg q2w | 343 | 0 | 0 | NA | NA | NA | NA | ||||
| Chemotherapy control | 309 | 0 | 0 | NA | NA | NA | NA | ||||
|
| |||||||||||
| Reck et al., 2016 [11] | RCTIII | NSCLC | PFS | Pembrolizumab 200 mg q3w | 154 | NA | 1 | NA | NA | NA | NA |
| Chemotherapy control | 150 | NA | 0 | NA | NA | NA | NA | ||||
|
| |||||||||||
| Ribas et al., 2015 [12] | RCT II | MM | ORR | Pembrolizumab 2 mg/kg q2w | 178 | 1 | 1 | NA | NA | NA | NA |
| Pembrolizumab 10 mg/kg q2w | 179 | 3 | 1 | NA | NA | NA | NA | ||||
| Chemotherapy control | 171 | 1 | 1 | NA | NA | NA | NA | ||||
|
| |||||||||||
| Rittmeyer et al., 2017 [13] | RCT II | NSCLC | OS | Atezolizumab 1200 mg q3w | 609 | NA | 0 | NA | NA | NA | NA |
| Chemotherapy control | 578 | NA | 1 | NA | NA | NA | NA | ||||
|
| |||||||||||
| Hodi et al., 2016 [14] | RCT II | MM | ORR | Ipilimumab 3 mg/kg q3w +nivolumab 1 mg/kg q3w |
94 | 2 | 2 | 11 | 2 | 17 | 2 |
| Ipilimumab 3 mg/kg q3w | 46 | 0 | 0 | 0 | 0 | 2 | 0 | ||||
|
| |||||||||||
| Antonia et al., 2016 [22] | RCT II | SCLC | ORR | Ipilimumab 3 mg/kg q3w +nivolumab 1 mg/kg q3w |
61 | NA | NA | 4 | 1 | 7 | 5 |
| Ipilimumab 1 mg/kg q3w +nivolumab 3 mg/kg q3w |
54 | NA | NA | 2 | 0 | 0 | 0 | ||||
| Nivolumab 3 mg/kg q2w | 98 | NA | NA | 1 | 1 | 0 | 0 | ||||
|
| |||||||||||
| Larkin et al., 2015 [15] | RCT III | MM | OS/PFS | Ipilimumab 3 mg/kg q3w +nivolumab 1 mg/kg q3w |
313 | NA | 2 | NA | NA | NA | 2 |
| Nivolumab 3 mg/kg q3w | 313 | NA | 1 | NA | NA | NA | 0 | ||||
| Ipilimumab 3 mg/kg q3w | 311 | NA | 1 | NA | NA | NA | 0 | ||||
|
| |||||||||||
| Robert et al., 2015 [16] | RCT III | MM | OS | Pembrolizumab 10 mg/kg q2w | 278 | NA | 0 | NA | NA | NA | NA |
| Pembrolizumab 10 mg/kg q3w | 277 | NA | 1 | NA | NA | NA | NA | ||||
| Ipilimumab 3 mg/kg q3w | 256 | NA | 0 | NA | NA | NA | NA | ||||
MM: melanoma; NSCLC: nonsmall cell lung cancer; DTIC: Dacarbazine; gp100: gp100 vaccine; DOX: docetaxel; OS: overall survival; ORR: objective response rate; NA: not available.